358 related articles for article (PubMed ID: 22262593)
1. When should case-only designs be used for safety monitoring of medical products?
Maclure M; Fireman B; Nelson JC; Hua W; Shoaibi A; Paredes A; Madigan D
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():50-61. PubMed ID: 22262593
[TBL] [Abstract][Full Text] [Related]
2. Design considerations in an active medical product safety monitoring system.
Gagne JJ; Fireman B; Ryan PB; Maclure M; Gerhard T; Toh S; Rassen JA; Nelson JC; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():32-40. PubMed ID: 22262591
[TBL] [Abstract][Full Text] [Related]
3. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
Rassen JA; Schneeweiss S
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
[TBL] [Abstract][Full Text] [Related]
4. A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies.
Takeuchi Y; Shinozaki T; Matsuyama Y
BMC Med Res Methodol; 2018 Jan; 18(1):4. PubMed ID: 29310575
[TBL] [Abstract][Full Text] [Related]
5. Use of self-controlled designs in pharmacoepidemiology.
Hallas J; Pottegård A
J Intern Med; 2014 Jun; 275(6):581-9. PubMed ID: 24635348
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data.
Nelson JC; Cook AJ; Yu O; Dominguez C; Zhao S; Greene SK; Fireman BH; Jacobsen SJ; Weintraub ES; Jackson LA
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():62-71. PubMed ID: 22262594
[TBL] [Abstract][Full Text] [Related]
7. Comparison of epidemiologic methods for active surveillance of vaccine safety.
McClure DL; Glanz JM; Xu S; Hambidge SJ; Mullooly JP; Baggs J
Vaccine; 2008 Jun; 26(26):3341-5. PubMed ID: 18462849
[TBL] [Abstract][Full Text] [Related]
8. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations.
Glanz JM; McClure DL; Xu S; Hambidge SJ; Lee M; Kolczak MS; Kleinman K; Mullooly JP; France EK
J Clin Epidemiol; 2006 Aug; 59(8):808-18. PubMed ID: 16828674
[TBL] [Abstract][Full Text] [Related]
9. Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.
Weldeselassie YG; Whitaker HJ; Farrington CP
Epidemiol Infect; 2011 Dec; 139(12):1805-17. PubMed ID: 21849099
[TBL] [Abstract][Full Text] [Related]
10. Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research.
Schneeweiss S; Stürmer T; Maclure M
Pharmacoepidemiol Drug Saf; 1997 Oct; 6 Suppl 3():S51-9. PubMed ID: 15073755
[TBL] [Abstract][Full Text] [Related]
11. Immortal time bias in pharmaco-epidemiology.
Suissa S
Am J Epidemiol; 2008 Feb; 167(4):492-9. PubMed ID: 18056625
[TBL] [Abstract][Full Text] [Related]
12. Epidemiologic studies: pitfalls in interpretation.
Westhoff CL
Dialogues Contracept; 1995; 4(5):5-6, 8. PubMed ID: 12288680
[TBL] [Abstract][Full Text] [Related]
13. The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction.
Platt R; Carnahan RM; Brown JS; Chrischilles E; Curtis LH; Hennessy S; Nelson JC; Racoosin JA; Robb M; Schneeweiss S; Toh S; Weiner MG
Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():1-8. PubMed ID: 22262586
[TBL] [Abstract][Full Text] [Related]
14. Case-only designs in pharmacoepidemiology: a systematic review.
Nordmann S; Biard L; Ravaud P; Esposito-Farèse M; Tubach F
PLoS One; 2012; 7(11):e49444. PubMed ID: 23166668
[TBL] [Abstract][Full Text] [Related]
15. Methodologic challenges to studying patient safety and comparative effectiveness.
Strom BL
Med Care; 2007 Oct; 45(10 Supl 2):S13-5. PubMed ID: 17909371
[TBL] [Abstract][Full Text] [Related]
16. Methods in epidemiology: observational study designs.
DiPietro NA
Pharmacotherapy; 2010 Oct; 30(10):973-84. PubMed ID: 20874034
[TBL] [Abstract][Full Text] [Related]
17. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
[TBL] [Abstract][Full Text] [Related]
18. The case-crossover study design in pharmacoepidemiology.
Delaney JA; Suissa S
Stat Methods Med Res; 2009 Feb; 18(1):53-65. PubMed ID: 18765504
[TBL] [Abstract][Full Text] [Related]
19. Self-controlled designs in pharmacoepidemiology involving electronic healthcare databases: a systematic review.
Gault N; Castañeda-Sanabria J; De Rycke Y; Guillo S; Foulon S; Tubach F
BMC Med Res Methodol; 2017 Feb; 17(1):25. PubMed ID: 28178924
[TBL] [Abstract][Full Text] [Related]
20. Bidirectional case-crossover designs for exposures with time trends.
Navidi W
Biometrics; 1998 Jun; 54(2):596-605. PubMed ID: 9629646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
